Hormonal
Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces substantial, clinically meaningful, and sustained weight reduction in adults with obesity (BMI ≥30 or ≥27 with comorbidities) when used as an adjunct to lifestyle intervention, demonstrating superior efficacy compared to selective GLP-1 receptor agonists.
If you have obesity (BMI ≥30, or ≥27 with health issues like high blood pressure or sleep apnea), tirzepatide is a once-weekly injection that works by mimicking gut hormones (GIP and GLP-1) to help you lose weight. It is used alongside a reduced-calorie diet and exercise. The dose starts low (2.5 mg) and increases every 4 weeks to minimize stomach issues, reaching up to 15 mg. Clinical trials are designed to show it causes more weight loss than older drugs like semaglutide.
Tirzepatide, a novel glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, showed greater weight reduction than selective GLP-1 receptor agonists in type 2 diabetes studies... In the SURMOUNT-1 trial, once-weekly tirzepatide provided substantial, clinically meaningful, and sustained reductions in body weight in participants without diabetes.
Why this rating
This is a clinical development program design paper; primary results for most trials are not yet published, relying on phase 1/2 data and trial design rationale.
Source
Tirzepatide for the treatment of obesity: Rationale and design of the <scp>SURMOUNT</scp> clinical development program
Carel W. le Roux et al. · Obesity · 2022
DOI 10.1002/oby.23612
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →